Australia's most trusted
source of pharma news
Posted 16 July 2025 AM
AstraZeneca has moved a step closer to securing funding for Enhertu outside breast cancer, but the UK pharma giant still needs to work on its economic model provided to the PBAC.
It comes after MSAC supported amending an existing MBS item for HER2 in situ hybridisation (ISH) testing to determine eligibility for access to PBS subsidised Enhertu in patients with metastatic HER2-positive gastric or gastroesophageal junction (G/GOJ) cancer following trastuzumab therapy, if recommended by the PBAC.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.